APO Research
Talk to an analyst

APO RESEARCH · REPORT

Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Outlook and Growth Opportunities 2026

22 December 2025196 pages

Choose your research edition.

Industry ResearchIdiopathic Thrombocytopenic Purpura (ITP) Therapeutics Industry Research Report 2026100 pages · $2,950 USDIndustry Growth & TrendsGlobal Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Industry Growth and Trends Forecast to 203261 pages · $3,450 USDMarket StructureGlobal Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032174 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market include Grifols Biologicals Inc., Amgen Inc, GlaxoSmithKline Plc and Roch, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market.

Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Segment by Company

Grifols Biologicals Inc.

Amgen Inc

GlaxoSmithKline Plc

Roch

Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Segment by Type

Thrombopoietin Receptor Agonists (TPO-RA)

Corticosteroids

Anti-D Immunoglobulin

Intravenous Immunoglobulin (IVIG)

Others

Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Segment by Application

Hospitals

Clinics

Others

Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics key companies, revenue, market share, and recent developments.

3. To split the Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics significant trends, drivers, influence factors in global and regions.

6. To analyze Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics industry.

Chapter 3: Detailed analysis of Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Industry Trends Table 2. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Industry Drivers Table 3. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Industry Opportunities and Challenges Table 4. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Industry Restraints Table 5. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Share by Company (2021-2026) Table 7. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Key Company Manufacturing Base & Headquarters Table 9. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Company, Product Type & Application Table 10. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Thrombopoietin Receptor Agonists (TPO-RA) Table 15. Significant Companies of Corticosteroids Table 16. Significant Companies of Anti-D Immunoglobulin Table 17. Significant Companies of Intravenous Immunoglobulin (IVIG) Table 18. Significant Companies of Others Table 19. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Type (2021-2026) Table 23. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Hospitals Table 25. Significant Companies of Clinics Table 26. Significant Companies of Others Table 27. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Application (2021-2026) Table 31. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Application (2027-2032) Table 32. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Region (2021-2026) Table 35. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Region (2027-2032) Table 37. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Market Share by Country (2021-2026) Table 40. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Market Share by Country (2027-2032) Table 42. Grifols Biologicals Inc. Company Information Table 43. Grifols Biologicals Inc. Business Overview Table 44. Grifols Biologicals Inc. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Grifols Biologicals Inc. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Product Portfolio Table 46. Grifols Biologicals Inc. Recent Development Table 47. Amgen Inc Company Information Table 48. Amgen Inc Business Overview Table 49. Amgen Inc Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Amgen Inc Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Product Portfolio Table 51. Amgen Inc Recent Development Table 52. GlaxoSmithKline Plc Company Information Table 53. GlaxoSmithKline Plc Business Overview Table 54. GlaxoSmithKline Plc Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. GlaxoSmithKline Plc Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Product Portfolio Table 56. GlaxoSmithKline Plc Recent Development Table 57. Roch Company Information Table 58. Roch Business Overview Table 59. Roch Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. Roch Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Product Portfolio Table 61. Roch Recent Development Table 62. Research Programs/Design for This Report Table 63. Authors List of This Report Table 64. Secondary Sources Table 65. Primary Sources List of Figures Figure 1. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Product Image Figure 2. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 4. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Thrombopoietin Receptor Agonists (TPO-RA) Image Figure 8. Corticosteroids Image Figure 9. Anti-D Immunoglobulin Image Figure 10. Intravenous Immunoglobulin (IVIG) Image Figure 11. Others Image Figure 12. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Type (2021-2032) Figure 15. Hospitals Image Figure 16. Clinics Image Figure 17. Others Image Figure 18. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Application (2021-2032) Figure 21. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 24. North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 30. South America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Thrombopoietin Receptor Agonists (TPO-RA)
  • Corticosteroids
  • Anti-D Immunoglobulin
  • Intravenous Immunoglobulin (IVIG)
  • Others
Applications
  • Hospitals
  • Clinics
  • Others
Companies covered
  • Grifols Biologicals Inc.
  • Amgen Inc
  • GlaxoSmithKline Plc
  • Roch

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Dynamics
  1. 2.1 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Industry Trends
  2. 2.2 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Industry Drivers
  3. 2.3 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Industry Opportunities and Challenges
  4. 2.4 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Industry Restraints
3 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market by Company
  1. 3.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Company Revenue Ranking in 2025
  2. 3.2 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Company (2021-2026)
  3. 3.3 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Company Ranking (2024-2026)
  4. 3.4 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Company Manufacturing Base and Headquarters
  5. 3.5 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Company Product Type and Application
  6. 3.6 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market by Type
  1. 4.1 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Type Introduction
  2. 4.1.1 Thrombopoietin Receptor Agonists (TPO-RA)
  3. 4.1.2 Corticosteroids
  4. 4.1.3 Anti-D Immunoglobulin
  5. 4.1.4 Intravenous Immunoglobulin (IVIG)
  6. 4.1.5 Others
  7. 4.2 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value by Type
  8. 4.2.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value by Type (2021-2032)
  10. 4.2.3 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Type (2021-2032)
5 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market by Application
  1. 5.1 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.1.3 Others
  5. 5.2 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value by Application
  6. 5.2.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value by Application (2021-2032)
  8. 5.2.3 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Application (2021-2032)
6 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Regional Value Analysis
  1. 6.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value by Region (2021-2032)
  3. 6.2.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value by Region: 2021-2026
  4. 6.2.2 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value (2021-2032)
  7. 6.3.2 North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value (2021-2032)
  10. 6.4.2 Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value (2021-2032)
  16. 6.6.2 South America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Country, 2025 VS 2032
7 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Country-level Value Analysis
  1. 7.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value by Country (2021-2032)
  3. 7.2.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value by Country (2021-2026)
  4. 7.2.2 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Grifols Biologicals Inc.
  2. 8.1.1 Grifols Biologicals Inc. Company Information
  3. 8.1.2 Grifols Biologicals Inc. Business Overview
  4. 8.1.3 Grifols Biologicals Inc. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Grifols Biologicals Inc. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Product Portfolio
  6. 8.1.5 Grifols Biologicals Inc. Recent Developments
  7. 8.2 Amgen Inc
  8. 8.2.1 Amgen Inc Company Information
  9. 8.2.2 Amgen Inc Business Overview
  10. 8.2.3 Amgen Inc Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Amgen Inc Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Product Portfolio
  12. 8.2.5 Amgen Inc Recent Developments
  13. 8.3 GlaxoSmithKline Plc
  14. 8.3.1 GlaxoSmithKline Plc Company Information
  15. 8.3.2 GlaxoSmithKline Plc Business Overview
  16. 8.3.3 GlaxoSmithKline Plc Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue and Gross Margin (2021-2026)
  17. 8.3.4 GlaxoSmithKline Plc Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Product Portfolio
  18. 8.3.5 GlaxoSmithKline Plc Recent Developments
  19. 8.4 Roch
  20. 8.4.1 Roch Company Information
  21. 8.4.2 Roch Business Overview
  22. 8.4.3 Roch Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Roch Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Product Portfolio
  24. 8.4.5 Roch Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst